Pfizer unveils ATLAS, an Interactive, website that provides global antibiotic resistance surveillance data across 60 countries

Website can help inform global health strategies to mitigate the threat of antimicrobial resistance.

Understanding evolving bacterial resistance patterns is a key element in managing the rise of antimicrobial resistance. To that end, ATLAS can not only help physicians select the most appropriate treatment choices for their patients, but also enable global health authorities to develop data-driven antimicrobial resistance mitigation strategies.

Mobile devices and applications provide many benefits for healthcare professionals including increased access to point of care tools, which have been shown to support better clinical decision making and improved patient outcomes. In response to this need, Pfizer also offers ATLAS as a mobile application to enable rapid access to important resistance information at the point of patient care.

ATLAS offers an interactive platform that enables physicians to evaluate data, conduct analyses, and export tables and figures that include parameters such as pathogen, region, specimen source and in vitro susceptibility data. The ATLAS database is updated every six months with new resistance data from healthcare institutions in more than 60 countries as these become available. ATLAS can be accessed by visiting: www.atlas-surveillance.com.

“An important aspect for physicians when treating patients is knowledge; knowledge of where certain resistant bacterial infections tend to occur and knowledge of which antibiotics remain effective against them,” said Dr Freda Lewis-Hall, Chief Medical Officer of Pfizer. “ATLAS underscores our continued commitment to providing patients and physicians with meaningful resources that can help ensure appropriate utilization of antibiotics and improve infection prevention and control.”